Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnox
- Development stage
- Phase 4
- Lead developer
- Naveh Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Magnox** is Naveh Pharma's proprietary oral magnesium dietary-supplement product, marketed principally as **Magnox 520**, which supplies 520 mg elemental magnesium per capsule. It is promoted for magnesium repletion and support of normal muscle function, including nocturnal leg-cramp relief. Naveh Pharma describes the product as a patented, Dead Sea-derived magnesium composition with enhanced intracellular absorption relative to commonly available magnesium preparations. ([navehpharma.com](https://www.navehpharma.com/products/magnesium-based-line/magnox-520/))
- Brand names
- MagnoxMagnox 520Magnox520Magnox-520
Beyond the preview
Go deeper on Magnox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Magnox.